Could a Pre-Surgery immune booster tame aggressive brain cancer?
NCT ID NCT07134842
First seen Apr 18, 2026 · Last updated Jun 15, 2026 · Updated 8 times
Summary
This early-phase study is testing whether giving the immunotherapy drug ipilimumab before standard surgery and chemoradiation is safe and can help control glioblastoma, a fast-growing brain cancer. About 16 adults with newly diagnosed glioblastoma will receive up to two doses of ipilimumab before their usual treatment. The main goals are to check for side effects and see if the drug shrinks or slows the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University College London Hospital
RECRUITINGLondon, Greater London, NW1 2PG, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.